Analysis of the U.S. Cancer Biomarker Testing Market

Targeted Sequencing of Tumor Mutations is on the Horizon

USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

This research service analyzes the U.S. cancer biomarker testing market from 2009 to 2017. Topics include an overview of the market, along with definitions, metrics, drivers, and restraints. Also offered is an evaluation of ongoing technology trends and major market competitors and their corresponding market shares and product offerings. Based on this analysis, revenue forecasts and growth rates are projected for each segment of the market. This study also provides cancer epidemiology trends, voice-of-customer research on oncologists, and the challenges and strategies for cancer biomarker validation.

Table of Contents

Analysis of the U.S. Cancer Biomarker Testing Market, U.S. Cancer Biomarker Testing MarketResearch ServiceExecutive SummaryMarket OverviewTotal U.S. Cancer Biomarker Testing SegmentIndustry TrendsExternal Challenges: Drivers and RestraintsForecasts and TrendsMarket Share and Competitive AnalysisProduct AnalysisEpidemiologyVoice-of-Customer ResearchCancer Biomarker Validation Challenges and StrategiesMolecular Cancer Biomarker Testing Segment BreakdownForecast and TrendsTraditional Cancer Biomarker Testing Segment BreakdownForecasts and TrendsThe Last WordConclusions and ImplicationsAppendixAppendix

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.